AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17075243 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients before weight restoration
Number of subjects: 26
Study 17075243 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients after weight restoration
Number of subjects: 26
Study 17075243 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study 14756642 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐pulsed 1320‐nm Nd:YAG laser
Number of subjects: 20
Study 14756642 — intervention group
Group type: COMPARATOR
Intervention: Long‐pulsed 1450‐nm diode laser
Number of subjects: 20
Study 14756642 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction scores
Number of subjects: 20
Study 14756642 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo microtopography measurements
Number of subjects: 20
Study 14756642 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of treatment
Number of subjects: 20
Study 11708314 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplement (10 g protein, 7 g carbohydrate, 3.3 g fat, and one-third of RDA of vitamins and minerals) ingested immediately after exercise.
Number of subjects: 17
Study 11708314 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) did not ingest the protein supplement.
Number of subjects: 17
Study 9514139 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg of AA, daily for the first week of life
Number of subjects: 51
Study 9514139 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 51
Study 8088970 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP-MgCl2
Number of subjects: 18
Study 8088970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3406600 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs or relaxation therapy
Number of subjects: 0
Study 3406600 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31129371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Telephone Counseling (ITC; eight proactive sessions/eight weeks of nicotine patches, plus discussion of the LCS results)
Number of subjects: 1330
Study 31129371 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC; three proactive telephone counseling sessions/two weeks of nicotine patches)
Number of subjects: 1330
Study 31129371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (ITC and UC)
Number of subjects: 1330
Study 31129371 — intervention group
Group type: EXPERIMENTAL
Intervention: Six SCALE trials (including LSTH)
Number of subjects: 1330
Study 30039526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation in group B (Bio‐Oss Collagen)
Number of subjects: 128
Study 30039526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation in groups A (guided bone regeneration) and C (chronic periodontitis)
Number of subjects: 128
Study 30039526 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C supplementation in group D (no bone grafting or periodontal disease)
Number of subjects: 128
Study 30039526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation for pain relief
Number of subjects: 128
Study 26780271 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) adjunct to scaling and root planing (SRP)
Number of subjects: 20
Study 26780271 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-surgical periodontal therapy (NSPT)
Number of subjects: 20
Study 24996197 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib 800 mg orally once-daily
Number of subjects: 502
Study 24996197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 22406155 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TB drug treatment
Number of subjects: 40
Study 19783386 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200, 400, or 600 mg)
Number of subjects: 12
Study 19783386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17645384 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy plus cardiac rehabilitation
Number of subjects: 68
Study 17645384 — intervention group
Group type: COMPARATOR
Intervention: Cardiac rehabilitation only
Number of subjects: 68
Study 17645384 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 68
Study 15846252 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for CAD (exercise electrocardiogram test and dipyridamole stress echocardiography)
Number of subjects: 141
Study 15846252 — intervention group
Group type: COMPARATOR
Intervention: Control (no screening)
Number of subjects: 141
Study 10961514 — intervention group
Group type: COMPARATOR
Intervention: Normal (22 degrees C/30% RH)
Number of subjects: 8
Study 10961514 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet (30 degrees C/85% RH)
Number of subjects: 8
Study 10961514 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot (40 degrees C/40% RH)
Number of subjects: 8
Study 10961514 — intervention group
Group type: EXPERIMENTAL
Intervention: Post exercise
Number of subjects: 8
Study 10961514 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight measurements
Number of subjects: 8
Study 9051540 — intervention group
Group type: COMPARATOR
Intervention: IV ondansetron 4 mg and saline
Number of subjects: 80
Study 9051540 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ondansetron 4 mg followed by IV dexamethasone 20 mg
Number of subjects: 80
Study 8358475 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tube stripping
Number of subjects: 16
Study 8358475 — intervention group
Group type: COMPARATOR
Intervention: No chest tube stripping
Number of subjects: 16
Study 3002987 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B polysaccharide and OMV vaccine
Number of subjects: 30
Study 3002987 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 30
Study 3403868 — intervention group
Group type: EXPERIMENTAL
Intervention: Theolan Suspension (administered every 12 hours)
Number of subjects: 27
Study 3403868 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline solution (administered every 8 hours)
Number of subjects: 27
Study 3403868 — intervention group
Group type: EXPERIMENTAL
Intervention: Theolan Suspension
Number of subjects: 27
Study 3403868 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline solution
Number of subjects: 27
Study 31915170 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised intervention including interactive responses and medication and follow-up reminders, in addition to usual care and general educational messages.
Number of subjects: 760
Study 31915170 — intervention group
Group type: COMPARATOR
Intervention: Usual care and general educational messages on medical knowledge.
Number of subjects: 760
Study 30849947 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy walking (4 km at low-moderate intensity)
Number of subjects: 89
Study 28011243 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Balloon (DEB)
Number of subjects: 182
Study 28011243 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-Eluting Stent (PES)
Number of subjects: 182
Study 26790201 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive dynamic scalp acupuncture therapy
Number of subjects: 70
Study 26790201 — intervention group
Group type: COMPARATOR
Intervention: Traditional scalp acupuncture therapy
Number of subjects: 70
Study 23143672 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized mailed CVD risk messages
Number of subjects: 435
Study 21569309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (titration up to the minimum vs maximum of the recommended dose range)
Number of subjects: 0
Study 21569309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (staying on sertraline)
Number of subjects: 0
Study 21569309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (augmentation with mirtazapine)
Number of subjects: 0
Study 21569309 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (switching from sertraline to mirtazapine)
Number of subjects: 0
Study 19594842 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS (10 Hz left prefrontal repetitive TMS, 20-minute sessions)
Number of subjects: 4
Study 19594842 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 4
Study 19594842 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS
Number of subjects: 4
Study 16491578 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable accelerations triggered by the experimenter
Number of subjects: 19
Study 16491578 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-triggered acceleration
Number of subjects: 19
Study 16491578 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable accelerations triggered by subjects pressing a button
Number of subjects: 19
Study 15605345 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation facilitation program
Number of subjects: 20
Study 15605345 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy (PT) care
Number of subjects: 20
Study 11370405 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug information from the pharmaceutical industry
Number of subjects: 0
Study 11370405 — intervention group
Group type: EXPERIMENTAL
Intervention: Producer independent information
Number of subjects: 0
Study 9232299 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring orbicularis oculi (OO)
Number of subjects: 30
Study 9232299 — intervention group
Group type: COMPARATOR
Intervention: Monitoring adductor pollicis (AP)
Number of subjects: 30
Study 9232299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (OO and AP)
Number of subjects: 30
Study 7683480 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (C) with estramustine phosphate (E)
Number of subjects: 99
Study 7683480 — intervention group
Group type: COMPARATOR
Intervention: Estramustine phosphate (E)
Number of subjects: 99
Study 2961688 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic factor (ANF) at 0.20 microgram/kg/min
Number of subjects: 8
Study 2961688 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic factor (ANF) at 0.45 microgram/kg/min
Number of subjects: 8
Study 2961688 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic factor (ANF) at 0.03 microgram/kg/min
Number of subjects: 8
Study 2961688 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic factor (ANF)
Number of subjects: 8
Study 2961688 — intervention group
Group type: COMPARATOR
Intervention: High sodium diet (200 mEq/day)
Number of subjects: 8
Study 31890625 — intervention group
Group type: EXPERIMENTAL
Intervention: Uni Virtual Clinic (UVC) intervention
Number of subjects: 200
Study 31890625 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 200
Study 26181001 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-training (including a manikin and access to a web-based video on PBLS)
Number of subjects: 58
Study 26181001 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led course (2-hour duration)
Number of subjects: 58
Study 26181001 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-training
Number of subjects: 58
Study 26181001 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-training and Instructor-led training
Number of subjects: 58
Study 24848990 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 0
Study 24848990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium 400 mg
Number of subjects: 0
Study 24848990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-poloxamer 400 mg
Number of subjects: 0
Study 24848990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24848990 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study 24128134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (initiated at 2 mg/d, adjusted to 6 to 8 ng/mL)
Number of subjects: 25
Study 24128134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 25
Study 24128134 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (control group)
Number of subjects: 25
Study 21403463 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP‐HBV+Hib vaccine (SIIL)
Number of subjects: 100
Study 21403463 — intervention group
Group type: COMPARATOR
Intervention: TritanrixHB+Hiberix vaccine (GSK)
Number of subjects: 100
Study 21403463 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose for both SIIL and GSK groups
Number of subjects: 100
Study 18715826 — intervention group
Group type: EXPERIMENTAL
Intervention: Access arm with diagnostic information from the implantable device and fluid alert algorithm.
Number of subjects: 2400
Study 18715826 — intervention group
Group type: COMPARATOR
Intervention: Control arm without access to diagnostic information.
Number of subjects: 2400
Study 18715826 — intervention group
Group type: EXPERIMENTAL
Intervention: Access arm with diagnostic information from the implantable device.
Number of subjects: 2400
Study 16574735 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Oxford PTA Scale (MOPTAS)
Number of subjects: 82
Study 16574735 — intervention group
Group type: COMPARATOR
Intervention: Westmead PTA Scale (WPTAS)
Number of subjects: 82
Study 16574735 — intervention group
Group type: COMPARATOR
Intervention: Galveston Orientation and Amnesia Test (GOAT)
Number of subjects: 82
Study 16574735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral measurements at time 1 and time 2
Number of subjects: 82
Study 16574735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive measurements between time 2 and time 3
Number of subjects: 82
Study 12704972 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (R)
Number of subjects: 133
Study 12704972 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 133
Study 10879992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine treatment for 6 weeks
Number of subjects: 0
Study 10879992 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine treatment for 1 week
Number of subjects: 0
Study 9095569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 21
Study 9095569 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 21
Study 8249653 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 35
Study 8249653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 3535490 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral milrinone therapy (10 +/- 1 weeks)
Number of subjects: 9
Study 3535490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone after withdrawal of oral drug for 24 hours
Number of subjects: 9
Study 3535490 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of oral milrinone
Number of subjects: 9
Study 31338575 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiadhesive agent
Number of subjects: 80
Study 31338575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiadhesive agent)
Number of subjects: 80
Study 29119530 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver resection
Number of subjects: 484
Study 29119530 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-scoring model based on AFP, tumour number, and Vp4 PVTT
Number of subjects: 484
Study 29119530 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomogram
Number of subjects: 484
Study 26876503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluency covered stent
Number of subjects: 258
Study 24641978 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute heroin administration
Number of subjects: 26
Study 24641978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22243563 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg)
Number of subjects: 0
Study 22243563 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (0.025 mg/kg)
Number of subjects: 0
Study 22243563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20411690 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric auto-titrating CPAP
Number of subjects: 109
Study 20411690 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 109
Study 20411690 — intervention group
Group type: COMPARATOR
Intervention: Fixed CPAP after polysomnography (control group)
Number of subjects: 109
Study 17667678 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpalatal arch fixed retention
Number of subjects: 30
Study 17667678 — intervention group
Group type: COMPARATOR
Intervention: No retention
Number of subjects: 30
Study 17667678 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 30
Study 16315875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine administration during chemotherapy
Number of subjects: 0
Study 16315875 — intervention group
Group type: COMPARATOR
Intervention: Non-administration of cimetidine during chemotherapy
Number of subjects: 0
Study 11782685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF (500 mg BID for 10 days)
Number of subjects: 170
Study 11782685 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg BID for 10 days)
Number of subjects: 170
Study 9440719 — intervention group
Group type: EXPERIMENTAL
Intervention: VMP (etoposide, mitoxantrone, and prednimustine)
Number of subjects: 130
Study 9440719 — intervention group
Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorobucin, vincristine, and prednisone)
Number of subjects: 130
Study 7912567 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR positive tumors
Number of subjects: 241
Study 7912567 — intervention group
Group type: COMPARATOR
Intervention: EGFR negative tumors
Number of subjects: 241
Study 7912567 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR and c-erbB-2 protein expressing group
Number of subjects: 241
Study 2563327 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treatment with massed exposure
Number of subjects: 0
Study 2563327 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treatment with spaced exposure
Number of subjects: 0
Study 2563327 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treatment with self-controlled exposure
Number of subjects: 0
Study 2563327 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treatment with therapist-controlled exposure
Number of subjects: 0
Study 31833974 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 31833974 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HER2 therapy
Number of subjects: 0
Study 31134724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan initiated ≥ 12-h pre-discharge
Number of subjects: 1002
Study 31134724 — intervention group
Group type: COMPARATOR
Intervention: Sacubitril/valsartan initiated between Days 1–14 post-discharge
Number of subjects: 1002
Study 28520886 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier device covering the anaesthesia workstation
Number of subjects: 42
Study 28520886 — intervention group
Group type: COMPARATOR
Intervention: Control group (no barrier device)
Number of subjects: 42
Study 27682868 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives (£15 for each LAI medication)
Number of subjects: 141
Study 27682868 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 141
Study 24930179 — intervention group
Group type: EXPERIMENTAL
Intervention: Training involving throwing with visual feedback during training
Number of subjects: 0
Study 24930179 — intervention group
Group type: COMPARATOR
Intervention: Training involving throwing without visual feedback
Number of subjects: 0
Study 24930179 — intervention group
Group type: EXPERIMENTAL
Intervention: Training involving throwing with visual feedback
Number of subjects: 0
Study 23098408 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for NPCs in advanced neonatal and obstetric care
Number of subjects: 50
Study 23098408 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 50
Study 20129316 — intervention group
Group type: EXPERIMENTAL
Intervention: Souvenaid (medical food)
Number of subjects: 225
Study 20129316 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 225
Study 17321159 — intervention group
Group type: EXPERIMENTAL
Intervention: ISB‐IV
Number of subjects: 84
Study 17321159 — intervention group
Group type: EXPERIMENTAL
Intervention: ISB‐IL
Number of subjects: 84
Study 17321159 — intervention group
Group type: EXPERIMENTAL
Intervention: IL
Number of subjects: 84
Study 17321159 — intervention group
Group type: COMPARATOR
Intervention: IV
Number of subjects: 84
Study 16277295 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of drifting gratings (spatially separated)
Number of subjects: 0
Study 16277295 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstimulus interval of at least 1000 ms
Number of subjects: 0
Study 16277295 — intervention group
Group type: EXPERIMENTAL
Intervention: Two reference speeds tested: 2 deg/s and 8 deg/s
Number of subjects: 0
Study 16277295 — intervention group
Group type: EXPERIMENTAL
Intervention: Staircase method of estimating thresholds
Number of subjects: 0
Study 12166571 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced follow‐up (EF)
Number of subjects: 109
Study 12166571 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow‐up (CF)
Number of subjects: 109
Study 9607059 — intervention group
Group type: EXPERIMENTAL
Intervention: Live human rotavirus vaccine 89-12 (10^5 p.f.u. dose-1)
Number of subjects: 42
Study 9607059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 11835845 — intervention group
Group type: EXPERIMENTAL
Intervention: Local homoharringtonine and dexamethasone treatment
Number of subjects: 54
Study 11835845 — intervention group
Group type: COMPARATOR
Intervention: Local dexamethasone treatment
Number of subjects: 54
Study 11835845 — intervention group
Group type: COMPARATOR
Intervention: No drug treatment (untreated group)
Number of subjects: 54
Study 15278645 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine solution (pH 7.12)
Number of subjects: 34